Skip to main content

Nouscom receives additional funding for cancer vaccines

| News

Nouscom receives additional funding for cancer vaccines


Nouscom has received an investment totalling 7 million euros from the Italian venture capital firm Angelini Ventures. The Basel-based biotech company will use the funding to advance the development of its cancer vaccines. In the autumn, it secured 67.5 million euros for the innovation.

The Basel-based biotech company Nouscom has received funding totalling 7 million euros, announced a statement. The investment was made by Angelini Ventures, the venture capital arm of the Italian Angelini Group, which specializes in pharmaceuticals, consumer goods, mechanical engineering and viticulture.

Nouscom is developing standardized and personalized cancer vaccines based on viral vectors that target neoantigens. The new funds will enable the company to drive forward the clinical development of its vaccines.The ongoing Phase 2 trial for NOUS-209, a vaccine for the treatment of metastatic colorectal cancer, is one area of focus. The company also aims to complete a phase 1b trial for cancer prophylaxis in carriers of Lynch syndrome.

Groundbreaking cancer treatments

In autumn 2023, Nouscom raised 67.5 million euros for the development of its cancer vaccines as part of a Series C financing. The main investors included Andera PartnersInnoBio 2 Fund and M Ventures.

“We are thrilled to extend our Series C financing round and welcome Angelini Ventures aboard,” Marina Udie, CEO of Nouscom, is quoted as saying. “Their partnership underscores our dedication to innovation and accelerates our pursuit of groundbreaking cancer treatments.”

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.